Whitecap Biosciences

Whitecap Biosciences is a pharmaceutical company founded in 2015, focusing on novel therapies for ophthalmic diseases, including the two leading causes of blindness in ophthalmology: glaucoma and geographic atrophy. The company is developing a compound named WB007, a highly potent α-2 adrenergic agonist intended for the indication of vision improvement in glaucoma patients. The company also plans to establish clinical programs for WB007 and WB006 targeting geographic atrophy.